Additionally, the company promoted Holger Wesche, PhD, from senior vice president, research to chief scientific officer.
Erbez previously served as chief business officer and chief financial officer of Zosano Pharma, a therapeutics company focused on migraine, from 2016 through 2018.
She also served as chief financial officer and executive vice president of Asterias Biotherapeutics and chief financial officer, secretary and treasurer of Raptor Pharmaceuticals, where she helped to navigate the company through a growth period that included its first drug approval and subsequent commercial launch.
Prior to Raptor, Erbez was a managing director, Healthcare Investment Banking at Collins Stewart, a Founder and Managing director at Beal Advisors, and a senior level investment banker at Jefferies and company, and Cowen and company. She has also held positions at the investment banks Hambrecht and Quist and Alex. Brown and Sons.
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases.
DuPont recognised with R&D 100 Award for innovation in healthcare
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
Kibow Biotech receives AANP Corporation of the Year Award
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award